Abstract
Pseudomyxoma peritonei (PMP) arising from urachal tumors is extremely rare. To our knowledge, natural history, tumor biological behaviour, morbidity, treatment, and prognosis of PMP arising from the urachus are determined by the associated PMP. Management of urachal tumors with associated PMP should be based on aggressive locorregional therapy with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, similar to PMP arising from other origins.
Copyright © 2010. Published by Elsevier Ltd.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / surgery*
-
Adult
-
Cystadenocarcinoma, Mucinous / diagnosis
-
Cystadenocarcinoma, Mucinous / drug therapy
-
Cystadenocarcinoma, Mucinous / surgery*
-
Humans
-
Magnetic Resonance Imaging
-
Male
-
Peritoneal Neoplasms / diagnosis
-
Peritoneal Neoplasms / drug therapy
-
Peritoneal Neoplasms / surgery*
-
Pseudomyxoma Peritonei / diagnosis
-
Pseudomyxoma Peritonei / drug therapy
-
Pseudomyxoma Peritonei / surgery*
-
Rare Diseases / diagnosis
-
Rare Diseases / drug therapy
-
Rare Diseases / surgery*
-
Retreatment
-
Tomography, X-Ray Computed
-
Urinary Bladder Neoplasms / diagnosis
-
Urinary Bladder Neoplasms / drug therapy
-
Urinary Bladder Neoplasms / surgery*